Neurogene Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
NGNE Nasdaq 2830 www.neurogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Neurogene Inc.

Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome - Jun 29th, 2026 5:00 am
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome - Jun 8th, 2026 5:30 am
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 2nd, 2026 2:01 pm
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates - May 12th, 2026 2:05 pm
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy - May 12th, 2026 4:00 am
We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth - May 5th, 2026 5:37 am
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy - Apr 28th, 2026 5:30 am
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors - Apr 20th, 2026 5:30 am
Neurogene: Q4 Earnings Snapshot - Mar 24th, 2026 5:46 am
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates - Mar 24th, 2026 5:30 am
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference - Mar 21st, 2026 1:02 am
Neurogene to Participate in Stifel 2026 Virtual CNS Forum - Mar 11th, 2026 5:30 am
Block upgraded, Duolingo downgraded: Wall Street's top analyst calls - Feb 27th, 2026 7:50 am
Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More - Feb 27th, 2026 5:59 am
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome - Feb 26th, 2026 2:01 pm
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit - Feb 14th, 2026 7:05 am
Neurogene to Participate in Upcoming Investor Conferences - Feb 5th, 2026 5:30 am
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 4th, 2026 2:01 pm
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Jan 12th, 2026 5:00 am
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 5:30 am